The post SciGen is pleased to announce a joint partnership with Zuellig Pharma Singapore appeared first on scigen.

July 11, 2023, Singapore – SciGen Pte Ltd (“SciGen”), a rapidly growing biopharmaceutical company, is pleased to announce the signing of a distribution agreement with Medic Plus Pharmaceuticals (Pty) Ltd (“Medic Plus”), one of Botswana’s fastest growing companies in the wholesale and distribution business of Pharmaceutical Products and Allied Substances. This strategic partnership aims to expand SciGen’s presence in the markets of Botswana, Namibia, Lesotho, and Zambia in the Southern African Region.

With Gensulin®, a high-quality European recombinant human insulin product, SciGen aims to revolutionize diabetes management in Southern Africa. The manufacturing facilities, stringent quality control measures, and commitment to patient-centric healthcare have contributed to Gensulin®’s recognition as an effective, safe, and stable product with 20 years of experience.

The partnership with Medic Plus will leverage their deep understanding of the Southern African market and extensive distribution network, enabling us to effectively reach patients in Botswana, Namibia, Lesotho, and Zambia. By combining our expertise and resources, we aim to ensure that Gensulin® is readily available to those in need, thereby improving access to quality diabetic care in the region.

SciGen’s dedication to promoting innovative healthcare solutions and improving patient lives aligns with Medic Plus Pharmaceuticals’ commitment to quality and excellence. This alliance represents a milestone for both companies and their shared vision of making a positive impact on healthcare in Southern Africa.

As part of this agreement, SciGen will commence the registration process in the aforementioned markets in the third quarter of 2023. The launch of Gensulin® is anticipated to take place in the first quarter of 2025, pending the successful completion of the registration process and regulatory approvals.

SciGen’s primary objective is to meet the growing need for cost-effective healthcare solutions in Africa, and the strategy of a range of Gensulin® and other products will be fulfilling this demand. This strategy offers a significant cost advantage over the branded counterparts without compromising efficacy or safety, making them an attractive option for patients. To ensure widespread availability and accessibility, the plan is to register Gensulin® in a maximum number of markets especially focusing on countries from South, East, and West African regions. It will pave the way for establishing long-term substantial partnerships and distribution networks with local healthcare providers, ensuring needy patients are supplied with high-quality and affordable products. Going forward will be adding more products to explore potential ways SciGen can collaborate to improve healthcare access in Africa.

About SciGen Pte Ltd

SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. We leverage our commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve our pipeline and product portfolio. Founded in the Asian Innovation Capital, Singapore in 1988, we currently have operations in Singapore, South Korea, Australia, China, Philippines and are present commercially in all 6 continents. With exceptional commercialization capabilities, regulatory expertise as well as international management experiences, and strategic partnerships built with industry and academic institutes, we strive to deliver hope and make a real and lasting difference to patients and their families. To learn more about SciGen, visit: www.scigen.com

About Medic Plus Pharmaceuticals (Pty) Ltd

Medic Plus is one of Botswana’s fastest-growing companies in the wholesale and distribution business of Pharmaceutical Products and Allied Substances. Focus on excellent customer care support by continuously setting bench-marking standards in the industry. Established in 2019 and registered with the Botswana Medicines Regulatory Authority, we focus on excellent customer care support by continuously setting bench-marking standards in the industry. We emphasize the effective, efficient, and safe handling, storage, and distribution of such products ensuring their identity and quality during all aspects of the wholesaling and distribution process. We deliver to all corners of Botswana and beyond with utmost efficiency while upholding the highest medicine handling standards. For more information, please visit: https://medicplus.co.bw/

The post SciGen Announces Distribution Agreement with Medic Plus Pharmaceuticals (Pty) Ltd to Extend Presence in Southern African Markets appeared first on scigen.

• SciGen and DKSH have entered into a partnership for DKSH to supply Zometa® to Vietnam market.  Once imported, the products will be distributed by local partners in Vietnam.
• Under the partnership DKSH will use their commercial footprint to expand access and availability of a key oncology medicine Zometa® in Vietnam
• SciGen will retain all international development responsibility for Zometa®, including regulatory and clinical development activities.

July 5, 2023, Vietnam – SciGen, a growing biopharmaceutical company,  and DKSH, a leading Market Expansion Services provider, have entered a partnership for the supply of Zometa®, a lifesaving oncology medicine, to Vietnam. By way of this partnership SciGen’s Zometa® will be made available to a wider population base in Vietnam utilising DKSH’s strong market expansion and commercialisation capabilities. The products will be distributed by local distributors engaged by DKSH.

DKSH is a leading Market Expansion Services provider with nearly 160 years of experience, operating in 37 markets globally. With a tailor-made, comprehensive portfolio of services, the DKSH Business Unit Healthcare is a trusted healthcare solutions partner across Asia and beyond. The strategic partnership with DKSH plays an important part in Scigen’s expansion into Vietnam.

Zometa® (Zoledronic acid) is a bone-targeted agent for skeletal complications in advanced cancers and multiple myeloma. The product is manufactured at state of the art manufacturing facilities in Europe.

Dr. Shazli Ahmed Khan, SciGen’s Region Commercial Head for Asia Growth Markets, said: “SciGen is actively exploring expansion opportunities across Asia region with an objective to enhance access to its portfolio for the people who need them the most. Vietnam is a key market in SciGen’s Asian footprint and the organisation is committed to partner with the local healthcare organisations to achieve this objective for benefit of Vietnamese patients.  July 5, 2023, marks a milestone for SciGen and DKSH’s partnership journey, to help Oncology patients together in Vietnam. At the forefront of this partnership remains a commitment to provide high-quality medicines and healthcare solutions to patients in Vietnam .”

Phillip Wray, General Director, DKSH Pharma Vietnam, said: “We are delighted to be a trusted partner to SciGen in expanding its business in Vietnam. By utilizing our global experience and local understanding, as well as collaboration with local distributors, we will share the same vision to improve accessibility of the high-quality oncology drug, Zometa, across Vietnam.”

For further information, please contact:
SciGen Communications
comms@scigen.com.sg

DKSH
Ly My Nhi,
Manager, Marketing & Communications
+84 938 958 999 
nhi.my.ly@dksh.com

About Zometa

Zometa® (Zoledronic acid), a highly potent bone-targeted bisphosphonate, is an inhibitor of osteoclastic bone resorption.

Zometa® is indicated for the treatment of hypercalcemia of malignancy and prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcemia) in patients with advanced malignancies involving bone.

About SciGen

SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. We leverage our commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve our pipeline and product portfolio. Founded in the Asian Innovation Capital, Singapore in 1988, we currently have operations in Singapore, South Korea, Australia, China, Philippines and present commercially in all 6 continents. With the exceptional commercialization capabilities, regulatory expertise as well as international management experiences, and strategic partnerships built with industry and academic institutes, we strive to deliver hope and make a real and lasting difference to patients and their families. To learn more about SciGen, visit: www.scigen.com

About DKSH

DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 37 markets with 32,600 specialists, generating net sales of CHF 11.3 billion in 2022. The DKSH Business Unit Healthcare is a trusted healthcare solutions partner across Asia and beyond. With around 7,990 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2022. www.dksh.com/hec

The post SciGen, DKSH enter into partnership to supply Oncology drug, Zometa® to Vietnam appeared first on scigen.

LTU-904, developed by RianCorp, an Australian medical device company dedicating to the development & production of medical laser products for photochemical applications in the field of Low-Level Laser Therapy (LLLT). In June 2021, SciGen entered into the distribution agreement with RianCorp of the novel therapy in Korea. According to the agreement, SciGen is responsible for the registration of LTU-904 in Korea and Post-Approval Marketing Activities. The product is approved by the Ministry of Food and Drug Safety (MFDS) in December 2022.

Lymphoedema, a potential side effect of postmastectomy or post radiation therapy, happens to 20% of breast cancer patients. The condition can present whilst undergoing treatment or within the years following treatment. LTU-904 is a novel Low Level Laser Therapy (LLLT) approved by the US FDA as Class I laser device to treat patients with lymphedema. According to the results of a randomized, double blind, placebo controlled, clinical trial for LTU-904 Laser Therapy’s Treating Post-Mastectomy Lymphoedema, the LTU-904 decreases affected limb volume and whole upper body fluid, as well as improves tonometry of upper arm and posterior torso in post mastectomy lymphoedema patients one to three months after treatment, of which has been approved its safety and efficacy to treat patients with Lymphoedema.

During the recent annual conference of Korean Society of Lymphedema (KSL), the representative organization for Lymphedema research and clinical practice in Korea, a presentation of “Low-level Laser Therapy in Secondary Lymphedema after Breast Cancer” was delivered. 

“A study (Kilmartin et al, 2020) reported in the area of efficacy, reduction of edema (circumference/volume reduction) was confirmed as the primary indicator, and the secondary indicator was pain reduction (VAS etc.), functional improvement (change in grip strength, shoulder range of motion), and quality of life were reported to have improved as a result of evaluating the indicators.”, stated by Eunju Yang, Academic Director of Korean Society of Lymphedema (KSL), also known as Researcher of the Institute of Convergence Science, Yonsei University.

“We are pleased to officially launch the LTU-904 in Seoul here today at the annual conference of KSL”, said by Mr. Henry Pyun, Head of Direct Market at SciGen. “At SciGen, we aim to provide innovative and affordable treatment to patients. This hand-held battery-powered device significantly benefits patients with lymphedema in a treatment that takes less time, requires fewer consultations, and has a lower overall cost. It provides therapists with a valuable new treatment option for patients with lymphedema.”

In addition to the Korean MFDS approval, the LTU-904 is approved by U.S. FDA in 2006 and by Australian TGA in 2009.

The post SciGen’s LTU-904, an Innovative Laser Treatment for Lymphedema Launched to Korean Market appeared first on scigen.